Table 2 Baseline characteristics of BMF analysis and all-treated populations at entry into TED12037
Characteristic | BMF analysis population (n = 21) | All-treated population (n = 43) |
|---|---|---|
Mean age, years (SD) | 63.5 (10.7) | 63.8 (10) |
Sex, n (%) | ||
Male | 12 (57) | 26 (60) |
Female | 9 (43) | 17 (40) |
Disease subtype, n (%) | ||
PMF | 12 (57) | 30 (70) |
Post-ET MF | 1 (5) | 2 (5) |
Post-PV MF | 8 (38) | 11 (26) |
Risk status [27], n (%) | ||
High | 8 (38) | 15 (35) |
Intermediate | 13 (62) | 28 (65) |
JAK2V617F mutation status, n (%) | ||
Positive | 19 (90) | 39 (91) |
Negative | 2 (10) | 4 (9) |
Last fedratinib dose in TED12037, mg/day | ||
120 | 3 (14) | 3 (7) |
240 | 2 (10) | 4 (9) |
360 | 1 (5) | 5 (12) |
400 | 0 | 1 (2) |
440 | 2 (10) | 4 (9) |
520 | 7 (33) | 11 (26) |
600 | 1 (5) | 3 (7) |
680 | 5 (24) | 12 (28) |
BMF grade, n (%) | ||
0 | 0 (0) | 0 (0) |
1 | 2 (10) | 2 (5) |
2 | 10 (48) | 10 (23) |
3 | 9 (43) | 10 (23)a,b |
Spleen size (cm), median (range) | 18 (4–34) | 18 (4–34) |
Haemoglobin (g/dL), median (range) | 9.7 (7.4–15.2) | 9.3 (7.3–15.2) |
White blood cells (×109/L), median (range) | 16.4 (2.1–103.3) | 14.9 (2.1–103.3) |